Citrate/heparin/taurolidine - CorMedix Pharmaceuticals
Alternative Names: Citrate/taurolidine/heparin; CRMD 003; CRMD 004; Defencath; Heparin/citrate/taurolidine; Heparin/taurolidine/citrate; Neutrolin; Taurolidine/citrate/heparin; Taurolidine/heparin/citrateLatest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator ND Partners
- Developer CorMedix
- Class Alkanesulfonic acids; Antibacterials; Anticoagulants; Antifungals; Citrates; Heparins; Small molecules; Thiadiazines
- Mechanism of Action Cell adhesion molecule inhibitors; Deoxyribonuclease I stimulants; Factor Xa inhibitors; Heparanase inhibitors; Inflammation mediator inhibitors; Lipopolysaccharide inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Catheter infections
Most Recent Events
- 27 Nov 2024 CorMedix initiates an expanded-access programme for Catheter infection (In prevention, In children, In adolescents, In adult, In the elderly) (NCT06707480)
- 30 Oct 2024 CorMedix plans to initiated a clinical trial for Total Parenteral Nutrition (In adults) and anticipates commencing patient enrollment in the first half of 2025
- 14 Aug 2024 CorMedix submits a complete clinical protocol to the FDA to gain further alignment for Total Parenteral Nutrition clinical trial